Sign in
WithdrawnPhase 1

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Key facts

Who runs it
GC Cell Corporation
Trial code
Status
Withdrawn
Phase
Phase 1
Started
31 Oct 2024
Expected to end
Feb 2029
Type of study
Interventional, 2 groups
Treatments tested
  • AB-201
  • Cyclophosphamide
  • Fludarabine
Record updated
24 January 2025
Why it stopped
Determined that enrollment would be limited due to the change in care setting.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • ECOG performance status 0 to 1
  • Histologically confirmed HER2 expressed breast or gastric/GEJ cancer IHC ≥ 2+ within 6 months prior to study entry
  • Confirmed diagnosis of an advanced/unresectable or metastatic HER2+ breast or gastric/GEJ cancer that is refractory to, or intolerable of standard treatment, or for which no standard treatment is available
  • Must have received prior cancer therapy: Subjects with breast cancer must have received ≥ 3 prior systemic therapies; subjects with gastric/GEJ cancer must have received ≥ 2 prior systemic therapy(ies); subjects with IHC 3+ or IHC 2+/ISH+ cancers must have received previous treatment with a HER2-targeting therapy

Who cannot take part

  • Unresolved toxicities from prior anticancer therapy
  • Severe disease progression or health deterioration within 2 weeks prior to lymphodepletion regimen
  • Known past or current malignancy other than inclusion diagnosis
  • Known clinically significant cardiac disease
  • Active central nervous system (CNS) metastases, or involvement of the CNS, unless there is a history of at least 3 months of sustained remission
  • Ongoing uncontrolled systemic infections requiring antibiotic, anti-fungal, or anti-viral therapy
  • History of sensitivity or intolerance to cyclophosphamide or fludarabine
  • Currently Pregnant or lactating

What happens in this trial

What the trial wants to find out

This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases, which are phase 1a and phase 1b. The primary objective of phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors.

The 2 groups in the trial

  • Phase 1a Dose EscalationTreatment being tested

    * Dose Escalation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression * Interventions: * Drug: AB-201 * Drug: Cyclophosphamide * Drug: Fludarabine

    Treatment: AB-201, Cyclophosphamide, and Fludarabine

  • Phase 1b Dose ExpansionTreatment being tested

    * Dose Confirmation of AB-201 in advanced metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma with HER2 overexpression * Interventions: * Drug: AB-201 * Drug: Cyclophosphamide * Drug: Fludarabine

    Treatment: AB-201, Cyclophosphamide, and Fludarabine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Open-label, Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced Human Epidermal Growth Factor Receptor 2 Positive(HER2+) Solid Tumors
Record updated
24 January 2025